BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38711158)

  • 1. Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
    Gan J; Huang M; Wang W; Fu G; Hu M; Zhong H; Ye X; Cao Q
    J Transl Med; 2024 May; 22(1):428. PubMed ID: 38711158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
    Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
    Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.
    Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å
    Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of miRNAs and DNA methylation identifies miR-132-3p as a tumor suppressor in lung adenocarcinoma.
    Su Y; Shetty A; Jiang F
    Thorac Cancer; 2020 Aug; 11(8):2112-2124. PubMed ID: 32500672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant CpG-methylation affects genes expression predicting survival in lung adenocarcinoma.
    He W; Ju D; Jie Z; Zhang A; Xing X; Yang Q
    Cancer Med; 2018 Nov; 7(11):5716-5726. PubMed ID: 30353687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of epigenetically regulated lncRNAs and DNA methylation in smokers with lung adenocarcinoma.
    Jung J; Lee YJ; Kim CH; Ahn S
    PLoS One; 2021; 16(3):e0247928. PubMed ID: 33684161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analyses of differences between solid and nonsolid predominant lung adenocarcinomas.
    Luo J; Ma K; Shi Y; Chen Z; Zhao M; Huang Y; Wang S; Xi J; Zhan C; Xu S; Wang Q
    Thorac Cancer; 2018 Dec; 9(12):1656-1663. PubMed ID: 30276966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
    Dong M; Yang Z; Li X; Zhang Z; Yin A
    Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma.
    Brativnyk A; Ankill J; Helland Å; Fleischer T
    Int J Cancer; 2024 Jul; 155(2):282-297. PubMed ID: 38489486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China.
    Wang J; Duan Y; Meng QH; Gong R; Guo C; Zhao Y; Zhang Y
    PLoS One; 2018; 13(10):e0203155. PubMed ID: 30286088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
    Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
    Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiomics analysis on DNA methylation and the expression of both messenger RNA and microRNA in lung adenocarcinoma.
    Yang Z; Liu B; Lin T; Zhang Y; Zhang L; Wang M
    J Cell Physiol; 2019 May; 234(5):7579-7586. PubMed ID: 30370535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method.
    Cai Q; He B; Xie H; Zhang P; Peng X; Zhang Y; Zhao Z; Wang X
    Cancer Med; 2020 Oct; 9(20):7488-7502. PubMed ID: 32860318
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma.
    Zhang L; Zhu G; Wang X; Liao X; Huang R; Huang C; Huang P; Zhang J; Wang P
    Oncol Rep; 2019 Sep; 42(3):1017-1034. PubMed ID: 31322267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.